- Home
- BHLB vs GPCR Comparison
BHLB vs GPCR Comparison
Compare BHLB & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHLB
- GPCR
- Stock Information
- Founded
- BHLB 1846
- GPCR 2016
- Country
- BHLB United States
- GPCR United States
- Employees
- BHLB N/A
- GPCR N/A
- Industry
- BHLB Banks
- GPCR
- Sector
- BHLB Finance
- GPCR
- Exchange
- BHLB Nasdaq
- GPCR Nasdaq
- Market Cap
- BHLB 1.2B
- GPCR 1.1B
- IPO Year
- BHLB 2000
- GPCR 2023
- Fundamental
- Price
- BHLB $26.52
- GPCR $23.82
- Analyst Decision
- BHLB Hold
- GPCR Strong Buy
- Analyst Count
- BHLB 5
- GPCR 9
- Target Price
- BHLB $32.70
- GPCR $77.50
- AVG Volume (30 Days)
- BHLB 500.0K
- GPCR 1.1M
- Earning Date
- BHLB 04-24-2025
- GPCR 05-08-2025
- Dividend Yield
- BHLB 2.71%
- GPCR N/A
- EPS Growth
- BHLB 392.17
- GPCR N/A
- EPS
- BHLB 2.46
- GPCR N/A
- Revenue
- BHLB $431,403,000.00
- GPCR N/A
- Revenue This Year
- BHLB $31.27
- GPCR N/A
- Revenue Next Year
- BHLB $78.77
- GPCR N/A
- P/E Ratio
- BHLB $10.79
- GPCR N/A
- Revenue Growth
- BHLB 33.05
- GPCR N/A
- 52 Week Low
- BHLB $20.76
- GPCR $13.22
- 52 Week High
- BHLB $32.36
- GPCR $62.74
- Technical
- Relative Strength Index (RSI)
- BHLB 62.18
- GPCR 51.16
- Support Level
- BHLB $24.50
- GPCR $25.06
- Resistance Level
- BHLB $27.13
- GPCR $27.50
- Average True Range (ATR)
- BHLB 0.48
- GPCR 1.86
- MACD
- BHLB 0.26
- GPCR -0.31
- Stochastic Oscillator
- BHLB 78.06
- GPCR 28.77
About BHLB Berkshire Hills Bancorp Inc.
Berkshire Hills Bancorp Inc is a holding company. It provides Commercial Banking, Retail Banking, Consumer Lending, Private Banking and Wealth Management services.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.